• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by SS Innovations International Inc.

    5/15/25 4:15:20 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care
    Get the next $SSII alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    SS Innovations International, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    05453U203

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    05453U203


    1Names of Reporting Persons

    Sudhir Srivastava, M.D.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    117,324,445.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    117,324,445.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    117,324,445.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    60.60 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Consists of (a) 112,926,514 shares of Common Stock of the Company held by Sushruta PVT LTD; (b) 32,000 shares of Common Stock of the Company held by Dr. Srivastava; and (c) Options held by Dr. Srivastava to purchase 4,364,931 shares of Common Stock of the Company. Dr. Srivastava has a 100% interest in Sushruta PVT LTD. Percentage in Row 11 is calculated based on 193,603,970 shares of common stock outstanding as of May 13, 2025, as reported in the issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.


    SCHEDULE 13G

    CUSIP No.
    05453U203


    1Names of Reporting Persons

    Sushruta PVT LTD
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BAHAMAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    112,926,514.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    112,926,514.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    112,926,514.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    58.33 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Row 5 and Row 7 consists of 112,926,514 shares of Common Stock of the Company held by Sushruta PVT LTD. Percentage in Row 11 is calculated based on 193,603,970 shares of common stock outstanding as of May 13, 2025, as reported in the issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SS Innovations International, Inc.
    (b)Address of issuer's principal executive offices:

    1600 SE 15th Street, #512 Fort Lauderdale, FL 33316
    Item 2. 
    (a)Name of person filing:

    (1) Sudhir Srivastava, M.D. (2) Sushruta PVT LTD
    (b)Address or principal business office or, if none, residence:

    The address for Sudhir Srivastava, M.D., Sushruta PVT LTD and Sudhir Srivastava Innovations PTE LTD is as follows: 1600 SE 15th Street, #512 Fort Lauderdale, FL 33316
    (c)Citizenship:

    Sudhir Srivastava, M.D. - USA Sushruta PVT LTD - Commonwealth of the Bahamas
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    05453U203
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (1) Sudhir Srivastava, M.D. - 117,324,445 (2) Sushruta PVT LTD - 112,926,514
    (b)Percent of class:

    (1) Sudhir Srivastava, M.D. - 60.60% (2) Sushruta PVT LTD - 58.33%. All calculations of percentage ownership herein are based upon an aggregate of 193,603,970 shares of common stock outstanding as of May 13, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the Securities and Exchange Commission on May 14, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (1) Sudhir Srivastava, M.D. - 117,324,445 (2) Sushruta PVT LTD - 112,926,514

     (ii) Shared power to vote or to direct the vote:

    (1) Sudhir Srivastava, M.D. - 0 (2) Sushruta PVT LTD - 0

     (iii) Sole power to dispose or to direct the disposition of:

    (1) Sudhir Srivastava, M.D. - 117,324,445 (2) Sushruta PVT LTD - 112,926,514

     (iv) Shared power to dispose or to direct the disposition of:

    (1) Sudhir Srivastava, M.D. - 0 (2) Sushruta PVT LTD - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    The shares of common stock referenced in Item 4, Section (a) above include shares held of record by Sushruta PVT LTD. Dr. Srivastava owns a 100% beneficial interest in Sushruta PVT LTD.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Sudhir Srivastava, M.D.
     
    Signature:/s/ Sudhir Srivastava
    Name/Title:Sudhir Srivastava, M.D.
    Date:05/15/2025
     
    Sushruta PVT LTD
     
    Signature:/s/ Sudhir Srivastava
    Name/Title:Sudhir Srivastava, M.D., Authorized Signatory
    Date:05/15/2025
    Exhibit Information

    JOINT FILING AGREEMENT

    Get the next $SSII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SSII

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

    FORT LAUDERDALE, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced preliminary unaudited revenue and other select operating metrics for the three and twelve months ended December 31, 2025. For the fourth quarter of 2025, the Company expects to report: Revenue of approximately $15.0 million, up 85% from revenue of $8.1 million in the fourth quarter of 2024.SSi Mantra installations of 37, up 68% from 22 installations in the fourth quarter of 2024. For the ful

    1/13/26 8:30:00 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer

    FORT LAUDERDALE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Milan Rao as the Company's Global Chief Operating Officer and Chief Financial Officer. The Global Chief Operating Officer role is a newly created position. Mr. Rao will succeed Naveen Kumar Amar as Chief Financial Officer following Mr. Amar's resignation from the Company for personal reasons. Mr. Rao will be based in the United States and will work closely with the Chairman a

    1/8/26 5:00:00 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations Develops New Instruments to Advance Robotic Surgery in Large, Underserved Patient Segments, including Pediatric and Cardiac Markets

    FORT LAUDERDALE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company has completed the development of five new 5-millimeter surgical instruments for clinical use across multiple specialties, including pediatric, cardiac, and head and neck surgery, among other procedures involving smaller anatomical structures. The newly developed 5-millimeter surgical instruments include a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasp

    1/6/26 8:30:00 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    $SSII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Rao Milan claimed ownership of 120,000 shares (SEC Form 3)

    3 - SS Innovations International, Inc. (0001676163) (Issuer)

    1/30/26 8:47:35 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    Amendment: COO - Americas Cohen Barry F gifted 25,500 shares, decreasing direct ownership by 0.32% to 7,838,088 units (SEC Form 4)

    4/A - SS Innovations International, Inc. (0001676163) (Issuer)

    1/21/26 4:16:26 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    Chairman and CEO Sudhir Srivastava received a gift of 10,000 shares (SEC Form 4)

    4 - SS Innovations International, Inc. (0001676163) (Issuer)

    1/21/26 4:15:21 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    $SSII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: COO - Americas Cohen Barry F bought $3,799 worth of shares (426 units at $8.92), increasing direct ownership by 0.00% to 8,866,888 units (SEC Form 4)

    4/A - SS Innovations International, Inc. (0001676163) (Issuer)

    6/30/25 6:55:24 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    $SSII
    SEC Filings

    View All

    SEC Form S-1 filed by SS Innovations International Inc.

    S-1 - SS Innovations International, Inc. (0001676163) (Filer)

    2/2/26 8:01:50 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SS Innovations International, Inc. (0001676163) (Filer)

    1/13/26 8:35:35 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations International Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - SS Innovations International, Inc. (0001676163) (Filer)

    1/8/26 5:05:54 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    $SSII
    Leadership Updates

    Live Leadership Updates

    View All

    SS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer

    FORT LAUDERDALE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Milan Rao as the Company's Global Chief Operating Officer and Chief Financial Officer. The Global Chief Operating Officer role is a newly created position. Mr. Rao will succeed Naveen Kumar Amar as Chief Financial Officer following Mr. Amar's resignation from the Company for personal reasons. Mr. Rao will be based in the United States and will work closely with the Chairman a

    1/8/26 5:00:00 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations Appoints Naveen Kumar Amar as Chief Financial Officer

    FORT LAUDERDALE, Fla., Sept. 26, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Naveen Kumar Amar as the Company's Chief Financial Officer, effective September 24, 2025. Mr. Amar is assuming the Chief Financial Officer role, on a permanent basis, from Dr. Vishwa Srivastava, who has served as the Company's Interim Chief Financial Officer since July 2025. Dr. Vishwa Srivastava will continue in his capacity as the Company's Chief Executive Officer – Asia

    9/26/25 8:30:00 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations Announces Chief Financial Officer Transition

    FORT LAUDERDALE, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Arvind Palaniappan as the Company's Interim Chief Financial Officer, effective May 1, 2025, pursuant to a planned leadership transition. Anup Sethi, SS Innovations' departing CFO, will remain available to advise the Company prior to the appointment of a permanent CFO.   SS Innovations has commenced a search process to identify and recruit a permanent successor for the CFO role

    5/2/25 8:30:00 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care